Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

The landscape for evidence generation in hematologic malignancies is rapidly evolving. While randomized controlled trials (RCTs) remain the gold standard in support of drug efficacy, approval and use, the supplemental use of real-world data (RWD), generated as part of routine healthcare delivery, an...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2022-05, Vol.53, p.100913-100913, Article 100913
Main Authors: Derman, Benjamin A., Belli, Andrew J., Battiwalla, Minoo, Hamadani, Mehdi, Kansagra, Ankit, Lazarus, Hillard M., Wang, Ching-Kun
Format: Article
Language:English
Subjects:
Hematologic Neoplasms - therapy
Humans
Real-world data
Real-world evidence
Therapeutic development
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The landscape for evidence generation in hematologic malignancies is rapidly evolving. While randomized controlled trials (RCTs) remain the gold standard in support of drug efficacy, approval and use, the supplemental use of real-world data (RWD), generated as part of routine healthcare delivery, and real-world evidence (RWE), the insights derived from RWD, in this setting has become increasingly common. There is a wide variety of sources of RWD, each with its own strengths and weaknesses that need to be considered when determining its appropriate use in RWE generation. RWD and RWE have historically been utilized in the post-approval setting to assess real-world application, efficacy, and safety of approved therapies. However, due to increasing awareness of the advantages of additional sources of information, RWE sourced from clinical data are being increasingly used to provide context for regulatory decision-making across several diseases including hematologic malignancies. Today, many commercial vendors offer fully aggregated, de-identified and standardized real-world clinical data. To maximize the potential of RWD and RWE, important considerations are needed to ensure patient privacy and to reduce the potential for biases and residual confounding. Continued collaboration among researchers, regulators and industry partners are needed to optimize evidence generation to ensure that new therapies reach patients as quickly and safely as possible.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2021.100913